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Can in-vitro chemoresponse assays help find new treatment
regimens for malignant gliomas?
Ute Linza, Baran Ulusb, Georg Neulohb, Hans Clusmannb, Markus Oertelb,
Kay Noltec, Joachim Weisc, Nicole Heussend and Joachim M. Gilsbachb
Various in-vitro chemosensitivity and resistance assays
(CSRAs) have been demonstrated to be helpful decision
aids for non-neurological tumors. Here, we evaluated the
performance characteristics of two CSRAs for glioblastoma
(GB) cells. The chemoresponse of fresh GB cells from
30 patients was studied in vitro using the ATP tumor
chemoresponse assay and the chemotherapy resistance
assay (CTR-Test). Both assay platforms provided
comparable results. Of seven different chemotherapeutic
drugs and drug combinations tested in vitro, treosulfan
plus cytarabine (TARA) was the most effective, followed
by nimustine (ACNU) plus teniposide (VM26) and
temozolomide (TMZ). Whereas ACNU/VM26 and TMZ
have proven their clinical value for malignant gliomas in
large randomized studies, TARA has not been successful
in newly diagnosed gliomas. This seeming discrepancy
between in vitro and clinical result might be explained by
the pharmacological behavior of treosulfan. Our results
show reasonable agreement between two cell-based
CSRAs. They appear to confirm the clinical effectiveness
of drugs used in GB treatment as long as pharmacological
preconditions such as overcoming the blood–brain barrier
are properly considered. Anti-Cancer Drugs 25:375–384 c
2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
Various in-vitro chemoresponse assays or chemosensitivity
and resistance assays (CSRAs) have been developed and
applied since the 1950s [1–5]. However, only after the
introduction of microtiter technology could the laborious
and time-consuming handling typical of the assays in the
early days of the technique be overcome. Meanwhile,
quantifiable semiautomated methods exist that render
these assays feasible for clinical application [6,7].
Many publications have demonstrated the predictive
value of these assays [8–12]. For various tumor entities
such as lung cancer [13], melanoma [14], and malignant
glioma [15], correlations between cell-based and gene
expression assays could be demonstrated. In Japan,
CSRAs are officially approved as ‘advanced clinical
medicine’ [16]. In other parts of the world, however,
they are still considered research tools [17,18].
Here, we present response data of glioblastoma (GB) cells to
two CSRAs, which substantiate that these assays might be
helpful clinical decision aids that deserve more attention.
Materials and methods
Tumor tissue specimens
From August 2008 to January 2013, a total of 33 GB
specimens were collected from 30 patients undergoing
resection of malignant glioma at the Department of
Neurosurgery of the RWTH Aachen University Hospital.
In three cases, not only samples of the newly diagnosed
tumor but also of the first recurrence were collected for
chemoresponse analysis. All patients provided written
informed consent for in-vitro testing of their tumor tissue
before surgery. The study protocol was approved by the
local ethics committee (EK-158/07) as part of trial
number DRKS00000264 registered with the German
Clinical Trials Register.
Each specimen was reviewed by two neuropathologists
(K.N. and J.W.) and classified according to the current
WHO classification of tumors of the central nervous
system [19].
When the diagnosis glioma grade IV was confirmed,
samples of at least 0.5 g were sent in RPMI medium by
carrier to the test laboratory Lance (Bonn, Germany) for
the ATP tumor chemoresponse assay (ATP-TCA). In 11
cases, the samples were split and additionally sent to a
second laboratory (TherapySelect, Heidelberg, Germany)
to perform a chemoresponse assay called ‘chemotherapy
resistance test’ (CTR-Test). Arrival of the tumor tissue at
the test laboratory was within 24 h after surgical resection
in all cases.
MGMT methylation status
MGMT gene silencing was determined by methylation-
specific PCR. DNA was isolated from the control blood
samples and – in most cases – from unfixed tumor tissue
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using the QIAamp DNA Mini Kit, and in a few cases from
formalin-fixed, paraffin-embedded tumor tissue using the
QIAamp DNA FFPE Tissue Kit. The Epitect Bisulfite Kit
was used for bisulfite treatment of the DNA and the
modified DNA was amplified using the Epitect MSP-Kit
with the primers described in Hegi et al. [20]. All kits were
purchased from Qiagen (Hilden, Germany). Fragment
analysis was performed using an ABI PRISM 310 Genetic
Analyzer (Applied Biosystems, Darmstadt, Germany).
ATP-TCA
Tissue processing and cell culture were performed at
Lance according to a published protocol [6].
Briefly, tumor tissue was dissociated to produce a cell
suspension. The cells were washed and purified by
centrifugation to remove debris. Viability was measured
by trypan blue exclusion. Viable cells were resuspended
in 96-well plates at a density of 7500 cells/well. In three
cases, parallel samples were also prepared with 22 500
cells. Each drug was tested in duplicate at six test drug
concentrations (TDC). The TDC levels were chosen
so that the reference concentration (TDC100) corre-
sponded to the peak plasma range found in human blood
(Table 1). The whole set covered the concentration range
from twice (TDC200) to 1/16th (TDC6.25) the refer-
ence concentration in two-fold dilutions. Negative
medium controls and positive controls with maximum
ATP inhibition complemented the test sets. After 5–6
days at 371C, the cells were lysed, and ATP was measured
in the luciferin–luciferase reaction.
Nine commercially available drugs were used as single
agents or combinations of up to three compounds (Table 2).
The results were expressed as %inhibition at concentration
c, and a sum index (SI) to express response was determined
as SI=600–SiInhib(ci) with ci=200, 100, 50, 25, 12.5, and
6.25% TDC. An SI of 600 corresponds to complete
resistance and an SI of 0 to full inhibition.
CTR-Test
Tissue processing and cell culture were performed at
TherapySelect, according to a published protocol [21].
In summary, tissue was mechanically and enzymatically
disrupted until spheroids could be isolated. The tumor
cells were plated at a density of 10 000 cells/well, drugs
were added, and the microplates were incubated for 72 h.
Tritiated thymidine (3H-thymidine) was added and
incubation was continued for another 48 h. Cells were
then harvested onto glass fiber filters and the uptake of
the radioactive thymidine into DNA was measured by
scintillation counting. Cultures without drug served as
negative controls and cells exposed to lethal doses of
cisplatin as positive controls. Results were reported as
extreme drug resistance (EDR) when proliferation was
1 SD above the median population density, low drug
resistance (LDR) when proliferation was 1 SD below the
median, and intermediate drug resistance (IDR) when
proliferation was between the SD limits. Limits for EDR,
LDR, and IDR were determined by a Bayesian algorithm,
unique for each agent tested [22].
The final concentrations for the single-drug assays were
as cited in Table 1. For dual drug combinations, the
agents were used in half the final concentration of
the single-drug assays.
Table 1 Chemotherapeutic drugs tested against GB in chemoresponse assays
Name (abbreviation) Chemical class/mechanism of action TDC100 (mmol/l) CTR (mmol/l)
Cytarabine (ARAC) Nucleoside analog/DNA mismatch 82 4
Lomustine (CCNU) Nitrosourea/direct alkylation 14 –
Nimustine (ACNU) Nitrosourea/direct alkylation 18 –
Procarbazine (PCB) Methylhydrazine/indirect alkylation 18 –
Temozolomide (TMZ) Tetrazine/indirect alkylation 258a 760
Teniposide (VM26) Epipodophyllotoxin/topoisomerase II inhibitor 30 –
Topotecan (TPT) Alkaloid/topoisomerase I inhibitor 2 0.2
Treosulfan (TREO) Dimethylsulfonate/indirect alkylation 180 18
Vincristine (VCR) Alkaloid/microtubule inhibitor 1 0.5
TDC100 corresponds to 100% test drug concentration for the ATP-TCA [6]. CTR stands for the final test concentration in the CTR-Test.
ACNU, aminomethylpyrimidinylmethylchloroethylnitrosourea; CCNU, chloroethylcyclohexylnitrosourea; CTR, chemotherapy resistance; GBs, glioblastomas; TCA, tumor
chemoresponse assay; TDC, test drug concentration.
aConcentration of active compound MTIC is 2% of TMZ.
Table 2 Rationale for the choice of the chemotherapeutic drugs
applied to the CSRAs in the present study
Name (abbreviation) Rationale
Temozolomide (TMZ) Present chemotherapeutic treatment standard
for GB
Nimustine/ACNU+ teniposide/
VM26 (ATEN)
According to randomized trial (NOA-1) equally
effective as TMZ
Procarbazine + lomustine/
CCNU+ vincristine (PCV)
Until recently, a frequently used combination for
malignant gliomas
Vincristine (VCR) Component of PCV, to serve as consistency
control
Topotecan (TPT) Same compound class as irinotecan but
presumably improved crossing of BBB
Temozolomide +nimustine/
ACNU (TA)
New combination of the most successful
compounds against GB
Treosulfan + cytarabine (TARA) Successful for extracranial multiresistant
cancers such as malignant melanoma; new
combination for brain tumors
ACNU, aminomethylpyrimidinylmethylchloroethylnitrosourea; BBB, blood–brain
barrier; CCNU, chloroethylcyclohexylnitrosourea; CSRA, chemosensitivity and
resistance assay; GB, glioblastoma.
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Statistical analysis
Continuous data are reported as means and corresponding
SDs. One-factor repeated measures analysis of variance
(rmANOVA) was used to assess differences between the
tested chemotherapeutic drugs in terms of relative
inhibition expressed as SI. The rmANOVA model
included SI as dependent variable and chemotherapeutic
drug as grouping factor. To account for the correlation
between the measurements, an unstructured covariance
structure was fitted to the data. To explore the validity of
the findings, several sensitivity analyses were performed,
including successive removal of patients with GB variants
in an rmANOVA model. The exclusion of samples from
patients with GB variants (for each variant and in
combination) does not alter the findings.
Applied tests were two-sided, and resulting P-values less
than an a level of 0.05 were considered to indicate
statistical significance. In the case of post-hoc compar-
isons, Bonferroni correction was applied. All statistical
analyses were performed using SAS statistical software,
V9.2 (SAS Institute Inc., Cary, North Carolina, USA)
under Windows XP.
Results
Histological grading of the 30 newly diagnosed tumor
samples and three recurrences revealed 23 ‘classical’ GBs.
Four GB samples contained foci of oligodendroglial
components, one met the criteria of gliosarcoma, one
was a giant cell GB, and one was a secondary GB.
Statistical analysis for all the results presented here was
performed with or without the GB variants to ensure that
they would not affect the outcome.
The rationale for choosing the various drugs and drug
combinations is summarized in Table 2.
ATP-TCA
GB specimens from surgical resections were exposed to
six different concentrations of the solutes in Table 2. All
assays were available for evaluation.
Table 3 Intrapatient variability of the ATP assay
A
Comparator Resistant Weakly sensitive Intermediate sensitive Highly sensitive
B (7500 cells)
Resistant 5 1
Weakly sensitive 4
Intermediate sensitive 3 1
Highly sensitive 7
C (22500 cells)
Resistant 2 2
Weakly sensitive 1 1
Intermediate sensitive 1 1
Highly sensitive 6
D (first recurrence)
Resistant 10 2 1
Weakly sensitive 1 2
Intermediate sensitive 1 1
Highly sensitive 2 1
Identical assay results 17 6 4 14
From five tumors, parallel samples were submitted to the seven test drugs of the ATP assay listed in Table 2 to determine the degree of variation (A vs. B and C,
respectively). In three cases, cells from the newly diagnosed glioblastoma and the first recurrence were submitted to the ATP assay (A vs. D).
Bold values indicate identical assay results (e.g. A resistant vs. B resistant or A highly sensitive vs. C highly sensitive, etc.).
Fig. 1
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Inhibition profile of glioblastomas to various test drugs in the
ATP-TCA. The total number of tumors was 30 for TARA, ATEN,
VCR, and TPT; 29 for TMZ; 24 for PCV; and 23 for TA, respectively.
For TARA, the positive SDs are shown as vertical bars. The
asterisks indicate P-values less than 0.0001 of the TARA curve in
relation to corresponding concentrations in all other curves. The
abbreviations of the drugs are TARA, treosulfan+ cytarabine ( );
TA, temozolomide+ACNU (~); ATEN, ACNU+ teniposide (X);
TMZ, temozolomide (K); VCR, vincristine (&); PCV,
procarbazine+CCNU+vincristine (’); TPT, topotecan (~).
ACNU, aminomethylpyrimidinylmethylchloroethylnitrosourea;
CCNU, chloroethylcyclohexylnitrosourea; TCA, tumor chemoresponse
assay; TDC, test drug concentration.
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From five tumors, two parallel samples each were sub-
mitted to the seven drug sets to study the reproducibility
and robustness of the assay. Twenty-eight of the 35
resulting tests (80%) yielded identical results (Table 3).
This included nine pairs where one of the assays
comprised voluntarily three times the standard number
of tumor cells (22 500 vs. 7500 cells/well) to check for
possible sampling effects.
The mean inhibition profile of all the GBs tested in the
ATP-TCA is illustrated in Fig. 1. Procarbazine–CCNU–
vincristine (PCV), vincristine (VCR), and topotecan
(TPT) had by far the lowest inhibitory effect on the
tumors. Even at the highest dose (TDC200), growth
inhibition hardly reached the 60% level. The four
remaining drug sets were able to induce nearly complete
inhibition at the highest dose level and still at least 80%
at the reference concentration TDC100. This difference
was significant (P<0.0001) as compared with PCV, VCR,
and TPT. Treosulfan plus cytarabine (TARA) exhibited
a very favorable dose gradient with a relatively flat
curve, illustrating growth inhibition already at moderate
concentration levels. ACNU/teniposide (ATEN) and
temozolomide alone (TMZ) or in combination with
ACNU (TA) revealed sigmoid curves spanning the whole
inhibition range from 100 to 0%.
Except for ATEN and TA (P=0.1748) or PCV and VCR
(P=0.0814), the differences in inhibition were signifi-
cant (PCV and TMZ: P=0.0101, TPT and VCR:
P=0.0005, all other drug combinations: P<0.0001).
When inhibition at individual concentration levels rather
than inhibition as a whole was compared, ATEN was
significantly more effective than TMZ at the lower TDCs
(TDC25: P<0.0152 and TDC12.5: P<0.0001) and
TARA was significantly more effective than all other
agents at rTDC50 (P<0.0001).
We further determined how many tumors demonstrated
at least 90% inhibition at TDC100 and four higher
threshold values up to 99.9% (Fig. 2). All five levels were
most often achieved with TARA (23, 18, 13, 12, and seven
of 30 cases, respectively). Of the other agents, only
ATEN achieved the highest level of inhibition, but only
in one case. PCV was the least effective. It did not cause
growth inhibition of at least 90% in any of the 24 tumors
tested.
The relative inhibition was also expressed as SI, a
measure for the overall growth inhibition. The mean
index of all samples tested was lowest for TARA (Fig. 3).
This difference was statistically significant in comparison
with all other agents (P<0.0001). The SI of ATEN was
also significantly lower than that of TMZ (P=0.0004),
PCV (P<0.0001), TPT (P<0.0001), and VCR (P<0.0001),
even when the gliosarcoma and the GBs with divergent
patterns of differentiation were excluded from the
analysis.
In three patients, we could study the behavior of the
primary tumor and the first recurrence. Of the 21
individual ATP assay samples, 13 yielded identical results
(62%, cf. Table 3). In four cases, the recurrent tumor
showed higher sensitivity and for three test drugs the
recurrent tumor was less sensitive. It turned out that two
Fig. 2
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of the three cases with reduced sensitivity were for TMZ,
the drug that all patients had received as first-line
chemotherapy (data not shown).
CTR-Test
A total of 15 tissue samples of 11 tumors were subjected
to the CTR assay in parallel to the ATP-TCA. Only seven
of these were evaluable for all agents. The choice of test
drugs could not be fully matched to the ATP-TCA
because at the time of the study not all agents were
validated for the CTR-Test. The following drugs were
applied for comparison with the ATP assay: TMZ, TPT,
VCR, and TARA.
In Fig. 4, an example of a CTR-Test result is shown in
comparison with the respective ATP assay. In this case,
Fig. 3
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the tumor displayed EDR for VCR, IDR for TMZ and
TPT, and LDR for TARA.
Six of the seven GBs evaluable demonstrated least
resistance to TARA (Table 4) as compared with TMZ,
VCR, and TPT. Only two of the tumors were classified as
IDR whereas the other five fell into the LDR category.
TMZ ranked second in the CTR assay with three tumors
in the LDR and four in the IDR group. The least
effective agent was VCR, with four of seven tumors
expressing EDR.
Discussion
The response of GB cells to various chemotherapeutic
drugs was studied by established in-vitro chemoresponse
assays. We used the ATP-TCA and in several cases the
CTR-Test in comparison. In retrospective analyses,
the ATP-TCA demonstrated a predictive accuracy of
70–90% for drug sensitivity and 90–100% for prediction of
clinical resistance [4,23]. The CTR-Test is optimized for
negative prediction or as drug exclusion test. Drugs that
showed extreme resistance in this assay were found to be
inactive in vivo in at least 95% of the cases [21].
Cell-based versus molecular CSRA
Rather than applying a genetic or protein marker assay to
determine chemoresponse of GB, we opted for two cell-
based assays because the current understanding of the
cellular chemoresistance mechanisms is still insufficient
to model all aspects involved. Single genes most often fall
short [24–26]. However, gene signatures or profiles might
also be of limited value for a heterogeneous tumor [27].
Therefore, it seems acceptable to adhere to the cell-
based approach considering the cell as a ‘black box’ where
inhibition of growth or cell death is the result of all active
mechanisms of resistance. This pragmatic strategy does
not require knowledge of the exact mechanisms of action.
It is sufficient to know which concentration levels are
reached in vivo and whether the drug of interest is able to
reach the target cells, for example, by crossing the blood–
brain barrier (BBB). This latter aspect is also a relevant
precondition for molecular assays, as is the fact that either
approach provides only a momentary snapshot of the
chemoresponse.
ATP-TCA
In accordance with findings by Andreotti et al. [4],
reproducibility of the ATP assay was B±20%. Variations
greater than ±20% occurred only at TDC less than or
equal to 25% or between different patients (Fig. 1). When
the ranking rather than the numerical values was
compared, 90% of the parallel samples yielded identical
chemoresponse levels. Even in the case of the 14 samples
having three times the cell number of the standard assay
(22 500 vs. 7500 cells/well), nine yielded identical results
(Table 3). Four assays demonstrated the next lowest
sensitivity level as compared with the standard set-up,
which would be expected if one assumes an increasing
number of resistant cells with increasing tumor cell load.
In only one case (7%), the assay with the three-fold cell
number showed slightly higher sensitivity than the
standard assay, which could be due to sample inhomo-
geneity. Overall, the ATP assay demonstrated robust and
consistent results after repeated sampling of GB tumor
tissue and within a wide range of tumor cells submitted.
GBs showed major differences in the response to the
solutes tested. Of the drugs that have already been
investigated for GB in phase II/III trials (TMZ, ATEN,
PCV, VCR, and TPT), ATEN showed the best inhibition
profile, followed by TMZ. VCR, TPT, and PCV followed
on a much lower level (Fig. 1). TARA yielded the best
profile of all drug sets, reaching close to 60% inhibition
even at the lowest drug concentration. The outcome of
the new combination TA lay between those of ATEN and
TMZ.
A similar ranking of the drugs was obtained when the
degree of inhibition at TDC100 was compared (Fig. 2).
We reasoned that the growth reduction at the end of a full
set of six cycles of chemotherapy would have to be at
least 50% to be clinically notable. If one considers the in-
vitro assay as a single cycle of chemotherapy, one would
need at least a reduction in cell survival of 90% in the
assay to achieve such an effect (0.96= 53%). Further, we
determined which percentage of tumor samples reached
95, 98.3, 99, and 99.9% growth reduction theoretically
corresponding to inhibition effects after six cycles of 74,
90, 94, and 99%, respectively.
Among the clinically established drugs, ATEN showed
the highest cytotoxic effect under our test conditions,
with 70% of the tumors inhibited in cell growth by
Table 4 Comparison of ATP-TCA and CTR-Test results
Sample number TMZ TARA VCR TPT
ATP
20 2 1 3 4
21 3 1 4 2
22 3 1 2 4
24 4 1 2 3
27 2 1 3 4
28 2 1 4 3
30 2 1 4 3
Mean rank 2.6 1.0 3.1 3.3
CTR
20 2 1 4 3
21 3 1 4 2
22 1 2 3 4
24 3 1 4 2
27 2 1 4 3
28 2 1 3 4
30 2 1 4 3
Mean rank 2.3 1.1 3.6 3.0
Rank 1 was assigned to the lowest sum index for ATP-TCA and to the lowest
resistance level in the case of the CTR assay, respectively. Ranks 2, 3, and 4
were assigned accordingly to the next higher indices.
CTR, chemotherapy resistance; TARA, treosulfan+ cytarabine; TCA, tumor
chemoresponse assay; TMZ, temozolomide; TPT, topotecan; VCR, vincristine.
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at least 90% at TDC100. Three percent of the samples
were inhibited by at least 99.9% at the same concentra-
tion.
Forty-eight percent of the GB samples tested with TMZ
(14/29) responded with inhibition of survival by at least
90%. Growth inhibition at the highest level of 99.9%
could not be achieved with TMZ at TDC100 for any of
the tumor specimens examined.
All the tumor samples tested against PCV were also
exposed to VCR to determine whether the cytotoxic
effect of PCV was mainly due to the lipophilic alkylating
agents PCB and CCNU or to the high-molecular
microtubule inhibitor VCR, which hardly crosses the
BBB [28,29]. It turned out that the survival curves after
exposure to PCV were indeed very similar to those after
VCR alone (Fig. 1).
Comparison of ATP-TCA and CTR-Test
One goal of the study was to determine whether the two
CSRAs provided similar results that would lead to similar
clinical recommendations. Therefore, we performed the
ATP-TCA and the CTR-Test in parallel for 15 samples of
11 tumors in the two laboratories with the operators
blinded to the results of the respective other. As some of
the chemotherapeutic drugs that we had used in the
ATP-TCA had not yet been validated for the CTR-Test,
we could only compare the four solutes TMZ, VCR, TPT,
and TARA (c.f. Fig. 4).
With only seven of the 15 samples evaluable, the CTR
assay was considerably more error-prone for GB samples
than the ATP assay, all samples of which were evaluable.
Due to the different methodological evaluations and the
limited number of parallel assays, we restricted data
analysis to a qualitative ranking of the substances
(Table 4).
In both assays, TARA showed by far the highest cytotoxic
effect or the lowest resistance level. TMZ ranked second,
and TPT and VCR were about equal on the third rank.
Despite the fact that the CTR assay is primarily
optimized to indicate drug resistance, whereas the ATP
assay claims to predict chemosensitivity, the two assay
platforms showed satisfying agreement.
Comparison between ATP-TCA and molecular markers
We compared the results of the ATP assay with the gene
activity of the repair enzyme MGMT. Transcription
of the MGMT gene is controlled by hypermethylation of
the promoter region. The gene is silenced when
methylated. Ignoring other mechanisms of resistance,
methylation should lead to higher sensitivity to alkylating
drugs because the enzyme is not available to repair
resulting DNA adducts [30,31]. Though limited, our in-
vitro results are in agreement with this hypothesis. There
was a clear trend for a lower SI and hence less resistance
when the MGMT gene was methylated. Only for TPT,
which is a topoisomerase I inhibitor, was this the other
way round. With the exception of PCV, the mean growth
inhibition at reference drug concentration TDC100 also
showed a tendency toward higher inhibition for tumors
with methylated MGMT by about three to five percen-
tage points (Table 5).
Comparison between ATP-TCA and clinical data
Our in-vitro results correspond well to published clinical
data. Recently, a randomized trial using ACNU plus
teniposide (NOA-1) was directly compared with EORTC
trial 26981, which applied TMZ [32,33] and a trend for
better results after treatment with ACNU plus teniposide
was observed. Our ATP assay results confirm this
advantage of ATEN in comparison with TMZ, as is
illustrated by the higher frequency of tumors inhibited by
at least 90% at reference concentration TDC100 (Fig. 2)
and the lower SI of ATEN (Fig. 3).
Our unfavorable in-vitro results for PCV are also in
accordance with the findings of two randomized phase III
trials for GB patients. Neither revealed a benefit of PCV
Table 5 Association between ATP-TCA and the expression of the repair gene MGMT
TMZ ATEN TARA VCR TPT PCV TA
Mean sum index 357.3 293.0 123.4 413.2 450.4 394.1 310.9
SD (overall) 94.2 93.4 91.9 101.6 116.9 103.2 55.2
Mean sum index 349.9 271.4 115.5 400.1 460.9 392.5 307.8
SD (mMGMT) 68.1 68.4 94.3 70.9 128.2 77.2 55.0
Mean sum index 375.0 317.5 137.8 412.9 450.1 395.4 313.2
SD (MGMT) 114.8 116.2 93.5 128.3 111.2 124.2 57.5
Mean growth inhibition at TDC100 (%) 86.5 88.5 93.8 43.7 48.2 45.2 87.1
SD (overall) 10.4 15.9 8.4 20.9 22.2 17.0 9.2
Mean growth inhibition at TDC100 (%) 88.3 91.0 95.7 46.6 50.1 45.1 88.7
SD (mMGMT) 8.4 13.8 6.7 13.7 23.8 14.1 8.7
Mean growth inhibition at TDC100 (%) 84.9 85.0 91.5 44.4 44.5 45.4 86.0
SD (MGMT) 11.7 18.7 10.0 26.1 21.0 19.7 9.8
# mMGMT 13 14 14 14 14 11 10
# MGMT 14 14 14 14 14 13 13
Mean sum index, mean growth inhibition at reference concentration (TDC100), and the respective SD are shown for all tumors and for those with methylated (mMGMT)
or unmethylated (MGMT) repair gene, respectively.
ATEN, ACNU+ teniposide; PCV, procarbazine +CCNU+ vincristine; TA, temozolomide+ACNU; TARA, treosulfan+ cytarabine; TCA, tumor chemoresponse assay;
TDC, test drug concentration; TMZ, temozolomide; TPT, topotecan; VCR, vincristine.
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in progression-free survival (PFS) or overall survival in
comparison with radiotherapy [34] or BCNU [35],
respectively.
Glioma cells have been reported to express high levels of
topoisomerase I [25]. Therefore, we were surprised by
the low cytotoxicity of TPT to the tumors investigated in
this study. However, in a phase II trial, Fisher et al. [36]
did not observe any benefit for GB patients treated with
TPT as compared with patients who had been irradiated
only.
In our own small patient cohort, PFS and overall survival
were longer when the ATP-TCA demonstrated higher
sensitivity. This trend remained for PFS even when the
degree of resection was considered. These results,
however, did not reach statistical significance (Table 6).
Another interesting association between the chemo-
response in vitro and the clinical behavior observed
deserves more attention. All patients received TMZ
treatment independent of and blinded to the ATP assay
result. However, when we compared the in-vitro result for
TMZ to the number of treatment cycles that were
administered, it seemed that patients whose tumors were
resistant to TMZ in vitro underwent fewer cycles of TMZ
than those with better in-vitro response. Only two of the
six patients in the ‘resistant’ group (TMZ=0) and seven
of the 14 patients in the ‘weak sensitivity’ group
(TMZ=1) received more than half of the scheduled
six cycles. The two patients in the intermediate
sensitivity level (TMZ=2), however, were exposed to
five and six cycles of TMZ, respectively. A potential
interpretation of this observation could be that patients
whose tumor shows resistance to TMZ in vitro tolerate
less of this drug or discontinue it early due to recurrence.
The disappointing clinical results of treosulfan – either
administered alone [37]) or in combination with the
nucleoside analog gemcitabine [38] – seem to be in clear
contrast to our in-vitro results, where TARA yielded by far
the best responses (cf. Figs 1–3).
However, there are several potential reasons why this
combination, which has successfully been used previously
for various extracranial tumors [39–41], was not success-
ful in GB patients despite its positive response in vitro.
The most important question is whether the drugs are
able to cross the BBB and reach the tumor. For
gemcitabine, this is still being debated [42,43]. Appro-
priate and convincing pharmacokinetic data are currently
missing. The related cytarabine reaches concentrations of
B5–10% of the plasma level in the cerebrospinal fluid
after intravenous administration [44].
In a review by Kortmann et al. [45], treosulfan was listed
as a chemotherapeutic drug with ‘good’ ability to cross
the BBB. However, quantitative pharmacokinetic data
relating to the central nervous system are lacking.
On the basis of its physicochemical characteristics, the
diffusion of treosulfan through the brain capillaries into
the brain tissue should be slow. Correspondingly, log BB,
the ratio of a compound’s concentration in brain tissue
versus blood [46], is low (log BB= – 2.5). However,
regarding the reactive metabolite diepoxybutane, the
calculated partition coefficient is more favorable (log
BB= – 0.3). As there are many examples where the cal-
culated partition coefficient log BB does not correspond
to the observed parameter, we submitted treosulfan to
a BBB model consisting of porcine brain capillary endo-
thelial cells to obtain additional information on the ability
of treosulfan to enter the brain. It turned out that the
amount crossing the BBB was more than one order of
magnitude lower than for TMZ (these data will be
published separately). In light of these observations, the
disappointing clinical results with treosulfan are no longer
surprising. However, the fact that GB cells respond rather
strongly to treosulfan and the nucleoside analogs in vitro
might argue for an attempt to improve the accessibility to
the brain and tumor tissue, for example, by convection-
enhanced delivery [47] or nanoparticulate transport
methods [48,49]. Considering the poor prognosis of GB
patients and the limited success of the present treatment
standards, this could be a worthwhile venture.
Conclusion
Our results show reasonable agreement between the two
cell-based CSRAs ATP-TCA and CTR-Test. Furthermore,
they seem to confirm the clinical effectiveness of
chemotherapeutic drugs used in GB therapy as long as
pharmacological preconditions such as penetration of the
BBB are properly considered. Under these conditions,
CSRAs have the potential to support the development of
new treatment regimens and deserve to be further
evaluated in larger prospective clinical trials.
Table 6 Association between tumor characteristics, in-vitro result,
and clinical outcome for 23 study patients
Variables PFS (days) OS (days)
All (23) 234 475
TMZ=0 (6) 174 436
TMZ=1 (14) 223 478
TMZ=2 (2) 531 630
GTR (8) 313 551
SPR (12) 169 406
TMZ=0+GTR (2) 191 828
TMZ=0+SPR (4) 166 241
TMZ=1+GTR (4) 266 372
TMZ=1+SPR (10) 204 521
TMZ=2+GTR (2) 531 630
TMZ=2+SPR (0) No data No data
Mean progression-free survival (PFS) and overall survival (OS) are given in days.
The number of patients is indicated in parentheses.
TMZ stands for the in-vitro result of the ATP-TCA for temozolomide, the drug that
all patients received as first-line chemotherapy: 0 = resistant, 1=weak sensitivity,
2= intermediate sensitivity. GTR corresponds to gross-total resection showing no
contrast enhancement in postoperative MRI, SPR, subtotal or partial resection.
No subgroup reached significance level P<0.05.
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